The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Hims & Hers (NYSE: HIMS) continues to grow at an astounding rate as the company grows subscribers and revenue per subscriber. But Hims & Hers stock is falling after earnings because investors are ...

With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears ...

Stocks are pulling back sharply from their premarket gains, after this morning's consumer confidence reading came in at 98.3 for February. This is well below expectations of 102.3 and a 7-point drop, ...